Table 1.

Examples of single/combination drug trials to address COVID‐19

Drug/combination	Clinicaltrials.gov registry number
Hydroxychloroquine, azithromycin, and tocilizumab	NCT04332094
Oseltamivir, favipiravir, hydroxychloroquine, darunavir, lopinavir	NCT04303299
Favipiravir combined with tocilizumab	NCT04310228
Lopinavir/ritonavir, ribavirin, and IFN‐beta combination	NCT04276688
Anakinra, siltuximab, and tocilizumab	NCT04330638
Losartan (nonhospitalized patients)	NCT04311177
Baricitinib and ritonavir	NCT04320277
Emtricitabine/tenofovir and hydroxychloroquine	NCT04334928
Lopinavir/ritonavir or hydroxychloroquine comparison	NCT04307693
Remdesivir	NCT04292899